Single-atom catalysis has revolutionized heterogeneous catalysis,which offers unparalleled atomic efficiency,well-defined active sites,and unique electronic properties.Unlike traditional nanoparticle catalysts,single-...Single-atom catalysis has revolutionized heterogeneous catalysis,which offers unparalleled atomic efficiency,well-defined active sites,and unique electronic properties.Unlike traditional nanoparticle catalysts,single-atom catalysts(SACs)maximize metal utilization and exhibit distinct catalytic behaviors due to their atomically dispersed nature.Over the past decade,SACs have demonstrated exceptional performance in various electrochemical and thermocatalytic reactions[1–3].However,despite these promising developments,several fundamental challenges hinder their practical implementation and large-scale commercialization.SACs face three major challenges:catalytic activity,stability,and scalable synthesis.Their isolated nature limits multi-electron transfer processes,making reaction kinetics highly sensitive to the coordination environment.To enhance catalytic activity,strategies such as secondary coordination effect,doping,and/or dual-atom configuration can be employed.Stability is another key issue,as single atoms tend to aggregate or undergo oxidation under reaction conditions,leading to performance decay.Strategies like strong metal-support interaction and ligand stabilization can be adopted to improve the durability of SACs.展开更多
To the Editor:Coronary artery disease(CAD)remains a leading cause of morbidity and mortality worldwide.[1]Atherosclerosis is a slowly progressive process;therefore,effective secondary prevention is commonly recommende...To the Editor:Coronary artery disease(CAD)remains a leading cause of morbidity and mortality worldwide.[1]Atherosclerosis is a slowly progressive process;therefore,effective secondary prevention is commonly recommended to halt or delay the progression of atherosclerosis toward subsequent cardiovascular events.[2]However,despite recent advances in medical and interventional therapies,patients with coronary atherosclerotic heart disease are still at high risk of cardiovascular events,resulting in an increasing global health expenditure.展开更多
文摘Single-atom catalysis has revolutionized heterogeneous catalysis,which offers unparalleled atomic efficiency,well-defined active sites,and unique electronic properties.Unlike traditional nanoparticle catalysts,single-atom catalysts(SACs)maximize metal utilization and exhibit distinct catalytic behaviors due to their atomically dispersed nature.Over the past decade,SACs have demonstrated exceptional performance in various electrochemical and thermocatalytic reactions[1–3].However,despite these promising developments,several fundamental challenges hinder their practical implementation and large-scale commercialization.SACs face three major challenges:catalytic activity,stability,and scalable synthesis.Their isolated nature limits multi-electron transfer processes,making reaction kinetics highly sensitive to the coordination environment.To enhance catalytic activity,strategies such as secondary coordination effect,doping,and/or dual-atom configuration can be employed.Stability is another key issue,as single atoms tend to aggregate or undergo oxidation under reaction conditions,leading to performance decay.Strategies like strong metal-support interaction and ligand stabilization can be adopted to improve the durability of SACs.
基金This work was supported in part by grants from the Chinese Natural Science Foundation(Nos.N82170275 and 82000420)Health Care Science Foundation(No.21BJZ06)+1 种基金Strengthening Foundation Plan(No.23M3001)Shanghai Talent Development Fund(No.2021064).
文摘To the Editor:Coronary artery disease(CAD)remains a leading cause of morbidity and mortality worldwide.[1]Atherosclerosis is a slowly progressive process;therefore,effective secondary prevention is commonly recommended to halt or delay the progression of atherosclerosis toward subsequent cardiovascular events.[2]However,despite recent advances in medical and interventional therapies,patients with coronary atherosclerotic heart disease are still at high risk of cardiovascular events,resulting in an increasing global health expenditure.
